GlassScriptPhysician profile
Lisa B Colasurdo
NPI 1447246616
$4,868.23
in general payments reported to CMS, 2019-2025
43 companies · $563 in 2025
The $563 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $996 · 2022: $1,399 · 2023: $980 · 2024: $930 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,151.74 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $952.02 | 2021-2025 | |
| Amgen INC. | $302.20 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $236.89 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $203.42 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $187.41 | 2021-2022 | |
| Esperion Therapeutics, INC. | $171.44 | 2021 | |
| Astellas Pharma US INC | $158.51 | 2022-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $108.34 | 2021 | |
| Abiomed | $97.24 | 2024-2025 | Impella |
| Glaxosmithkline, LLC. | $97.17 | 2021-2024 | Shingrix |
| Daiichi Sankyo INC. | $96.39 | 2022-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $86.61 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.58 | 2022-2023 | Xifaxan |
| Novo Nordisk INC | $80.89 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $78.78 | 2022-2024 | Zepbound, Jardiance |
| Amarin Pharma, INC. | $66.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.29 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $58.23 | 2023-2024 | Gemtesa |
| Pfizer INC. | $55.03 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $50.78 | 2022-2023 | |
| Inari Medical, INC. | $46.33 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Halozyme INC | $38.39 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.91 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $31.03 | 2022-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Corium, LLC | $28.78 | 2023 | Azstarys |
| Medtronic, INC. | $28.50 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $28.23 | 2023-2024 | Quviviq |
| Antares Pharma, INC. | $27.76 | 2022-2024 | Xyosted |
| Recor Medical INC | $25.85 | 2024 | Paradise Renal Denervation System |
| Dexcom, INC. | $24.03 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $19.14 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.68 | 2023 | Xyosted, Qelbree |
| Agios Pharmaceuticals, INC. | $15.10 | 2023 | Pyrukynd |
| Cranial Technologies, INC | $13.77 | 2023 | Doc Band |
| Corcept Therapeutics | $13.63 | 2024 | Korlym |
| Teva Pharmaceuticals USA, INC. | $13.33 | 2022 | |
| Exact Sciences Corporation | $13.25 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.20 | 2023 | Seglentis, Livalo |
| Evofem Biosciences, INC. | $12.93 | 2021 | |
| Almatica Pharma LLC | $11.97 | 2021 | |
| Sanofi Pasteur INC. | $11.85 | 2021 | |
| Acadia Pharmaceuticals INC | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Colasurdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.